SynthesisJournal of nephrology2022
The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis.
Synthesis in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Direct-Acting Antiviral Therapy and Long-Term Outcomes in Dialysis Patients With Hepatitis C: A Real-world Cohort Study.Open forum infectious diseases · 2026Article
- Hepatitis C Virus Infection at the Start of Hemodialysis and During Early Follow-up: Evidence from Two Dialysis Centers.Journal of epidemiology and global health · 2026Observational
- Seroprevalence and Demographic Distribution of Blood-Borne Viral Infections among Hemodialysis Patients in Sudan: A Multicenter Study from Conflict-Affected Khartoum State.Virology journal · 2026Article
- Moving Toward Hepatitis C Elimination in Haemodialysis: HCV Antigen as a Practical Screening Alternative.Cureus · 2026Article
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- Article
- Hepatitis C virus among hemodialysis patients: burden, risks, and prevention in resource-limited regions.International urology and nephrology · 2025Observational
- An Immuno-Fragile Profile Is Associated with Mortality Risk in Patients with Chronic Kidney Disease.Biomedicines · 2025Article
- Anti-hepatitis C virus threshold value in predicting hepatitis C virus viremia in hemodialysis patients.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review.Medicina (Kaunas, Lithuania) · 2024Observational
- Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024Review
- The Seroprevalence of Hepatitis C Virus (HCV) in Hemodialysis Patients in Oman: A National Cross-Sectional Study.Journal of epidemiology and global health · 2023Article
- Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers.International urology and nephrology · 2023Article
- Hepatitis C virus (HCV) in dialysis units: where are we now?Journal of nephrology · 2023Article
- Progress in the Detection of Erythropoietin in Blood, Urine, and Tissue.Molecules (Basel, Switzerland) · 2023Review
- A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease.PloS one · 2023Article
- Brazilian Dialysis Survey from 1999 to 2023: trends in demographics, nutritional status, primary disease, and viral serology.Jornal brasileiro de nefrologiaArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe worldwide burden of HCV infection among hemodialysis patients has not been systematically examined.
methodsA systematic literature search was conducted in MEDLINE and Scopus to determine the worldwide prevalence of HCV infection, risk factors, and clinical outcomes among hemodialysis patients. Random-effect models and meta-regressions were used to generate pooled estimates and assess heterogeneity.
resultsFour hundred and seven studies with 1,302,167 participants were analyzed. The pooled prevalence of HCV infection was 21%. The highest prevalence was observed in Africa (28%) and low-income countries (48.5%). A significant prevalence decline was observed following the publication year and was also inversely related to GDP and total population of each country. Factors associated with HCV positivity included younger age, longer dialysis duration, more blood transfusions, and dialyzer reuse. The pooled unadjusted hazard ratio for all-cause mortality was 1.12 (95% CI 1.03-1.22), and the adjusted hazard ratio was 1.21 (95% CI 1.12-1.30) in HCV-infected compared to non-HCV infected patients.
conclusionsHCV infection among hemodialysis patients is a worldwide shared burden and is associated with a higher risk of death. Avoiding unnecessary blood transfusion and dialyzer reuse should be encouraged to prevent HCV transmission in hemodialysis units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.